Takeda's Adcetris (brentuximab vedotin) + AVD Receives EU Approval for CD30+ Stage IV Hodgkin Lymphoma (HL) in Adults
Shots:
- The approval is based on P-III ECHELON-1 study result assessing Adcetris + AVD (adriamycin- vinblastine and dacarbazine) vs ABVD (adriamycin- bleomycin- vinblastine and dacarbazine) in patients with previously untreated CD30-positive and has met its 1EPs with 23% reduction in risk progression & improvement in PFS
- According to 2009 deal b/w Seattle Genetics & Takeda for Adcetris ((SGN-35)- Seattle to receive $30M milestone on Adcetris' EU approval and has commercialization rights in the US and Canada. Takeda to get WW commercialization rights for Adcetris (Ex-the US & Canada)
- ADCETRIS- IV is an antibody-drug conjugate (ADC) with anti-CD30 mAb and has received the US FDA approval for 6 indications- Health Canada approval for r/r Hodgkin Lymphoma and sALCL in 2013 & marketed in 70 countries
- - Ref: Takeda- Seattle Genetics | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
